Multicenter Study of Phase II With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet ®), Vincristine, Prednisone, (R-COMP) in Non-Hodgkin's Lymphoma Diffuse Large B Cell in Cardiopathic Patients
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Feasibility of R-COMP in cardiopathic patients
2 years
Yes
Michele Spina, MD
Study Director
Centro di riferimento Oncologico di Aviano
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
IIL-HEART01
NCT01009970
May 2010
May 2012
Name | Location |
---|